Коэнзим Q10 (Убихинон)

Coenzyme Q10 is not a marketing ingredient with vague claims. It has a fifty-year scientific history, randomized clinical trials, and a concrete biochemical mechanism that explains exactly why its concentration drops in inflamed periodontal tissue. Here is what the evidence actually says.

What It Is

Ubiquinone (2,3-dimethoxy-5-methyl-6-polyisoprenyl-1,4-benzoquinone) is a fat-soluble compound synthesized endogenously in every human cell. The name comes from Latin ubique — "everywhere" — because CoQ10 is present in all cell types.

The molecule has two functional parts. The benzoquinone ring provides redox activity: CoQ10 switches reversibly between its oxidized (ubiquinone) and reduced (ubiquinol) forms, accepting and donating electrons. The isoprenoid tail of ten units (hence "Q10") anchors the molecule in the lipid bilayer of cell membranes.

CoQ10 serves two distinct physiological roles. First, it is an essential electron carrier in the mitochondrial respiratory chain — without it, cells cannot produce ATP efficiently. Second, it is a fat-soluble antioxidant that neutralizes free radicals directly within the membrane lipid bilayer, where water-soluble antioxidants like vitamin C and glutathione cannot reach.

How It Works in Periodontal Tissue

In 1971, Littarru et al. published a landmark finding in PNAS (PMID: 5289867): gingival biopsies from patients with periodontal disease showed significantly depleted CoQ10 levels compared to healthy tissue. This was the first direct link between ubiquinone deficiency and inflammatory periodontal pathology.

A 1974 follow-up (Nakamura et al., PMID: 4151519) found that roughly 60% of diseased gingival specimens showed enzymatic CoQ10 deficiency, compared to only 20% in healthy controls.

The mechanism operates on multiple levels:

Oxidative stress as the central driver. In periodontitis, neutrophils and macrophages flooding the site produce reactive oxygen species (ROS) — superoxide, hydrogen peroxide, hydroxyl radicals. These attack cell membranes via lipid peroxidation (LPO), and LPO products (malondialdehyde, 4-HNE) amplify inflammatory cytokine signals (IL-1β, TNF-α, IL-6).

CoQ10 as membrane antioxidant. Ubiquinol intercepts lipid peroxyl radicals inside the membrane before they can initiate chain reactions. It also regenerates oxidized vitamin E (α-tocopherol), extending the antioxidant network. CoQ10 is thus not merely a standalone antioxidant but a hub in the membrane-protective system.

Mitochondrial protection. Chronic inflammation impairs mitochondrial respiration in periodontal cells. CoQ10 deficiency compounds this: reduced electron transport efficiency increases electron "leakage" to molecular oxygen, generating more superoxide — a vicious cycle where inflammation depletes CoQ10 and depleted CoQ10 drives further oxidative damage.

Clinical Evidence

Topical application (gels, intra-pocket). A randomized split-mouth trial by Chatterjee et al. (2012, PMID: 23055584) in 40 chronic periodontitis patients compared four treatment arms. After 6 weeks, intra-pocket Q10 combined with scaling and root planing (SRP) produced the best outcomes for plaque index, bleeding index, and pocket depth. Q10 functioned as an adjuvant — mechanical debridement remained essential.

Systemic supplementation. A 2025 systematic review (Alzoman et al., PMID: 39920883) synthesizing 10 randomized trials found that oral CoQ10 (120 mg/day) combined with SRP produced a statistically significant 0.41 mm greater reduction in probing depth and 0.52 mm greater clinical attachment level gain versus SRP alone.

What does not work. CoQ10 in toothpaste without any professional intervention is the least-studied scenario. Most positive results come from intra-pocket delivery or systemic supplementation. Toothpaste CoQ10 at 0.05–0.1% likely provides a preventive rather than therapeutic effect due to the brief contact time and poor mucosal penetration of a fat-soluble molecule.

| Delivery Form | Evidence Level | Effect | Applicable in Toothpaste | |---|---|---|---| | Intra-pocket gel | High (RCT) | Significant | No | | Oral supplementation | Moderate (meta-analysis) | Moderate | No | | Topical gingival gel | Moderate (RCT) | Moderate | Partial | | Toothpaste 0.1% | Limited data | Likely preventive | Yes |

Safety

CoQ10 is endogenously synthesized and present in common foods (meat, fish, nuts). It has an excellent safety record. Systemic doses up to 1200 mg/day have been well-tolerated in trials lasting up to 16 months, with mild gastrointestinal symptoms in a small subset at high doses.

Topical oral use at the concentrations found in dental products (0.05–0.1%) carries no documented adverse effects. No hypersensitivity reactions have been reported in published periodontal trials.

EU Cosmetics Regulation and FDA place no concentration limits on ubiquinone in cosmetic/hygiene products. Note: at systemic doses, CoQ10 may reduce the anticoagulant effect of warfarin — irrelevant for toothpaste application given negligible systemic absorption.

QDRO Position

CoQ10 is a candidate for the v.pro line, which targets professional-grade gum care. The case rests on three pillars: documented biochemical deficiency in inflamed periodontal tissue (measured, not theoretical); randomized clinical evidence supporting its adjunctive use; and a good fit with the existing ingredient system — zinc citrate controls biofilm, CPC suppresses pathogens, allantoin supports epithelial regeneration, and CoQ10 adds the membrane antioxidant layer that is otherwise missing.

Honest caveat: at toothpaste concentrations, CoQ10 provides a preventive contribution, not a clinical treatment. Patients with active periodontitis need professional intervention. The paste supports the interval between dental visits.

---

Sources:

• Littarru GP et al. (1971). Deficiency of Coenzyme Q10 in Gingival Tissue from Patients with Periodontal Disease. Proc Natl Acad Sci USA. PMID: 5289867
• Nakamura R et al. (1974). Study of CoQ10-Enzymes in Gingiva from Patients with Periodontal Disease and Evidence for a Deficiency of Coenzyme Q10. Proc Natl Acad Sci USA. PMID: 4151519
• Wilkinson EG et al. (1976). Bioenergetics in Clinical Medicine VI. Adjunctive Treatment of Periodontal Disease with Coenzyme Q10. Res Commun Chem Pathol Pharmacol. PMID: 785563
• Chatterjee A et al. (2012). Clinical Evaluation of Topical Application of Perio-Q Gel (Coenzyme Q10) in Chronic Periodontitis Patients. J Indian Soc Periodontol. PMID: 23055584
• Alzoman HA et al. (2025). Clinical Efficacy of Adjunctive Use of Coenzyme Q10 in Non-Surgical Periodontal Treatment: A Systematic Review. J Periodontal Res. PMID: 39920883